# Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

> **NCT02181738** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 294 (actual)

## Conditions studied

- Hodgkin Disease

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Doxorubicin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT02181738
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-12
- **Primary completion:** 2017-08-31
- **Final completion:** 2022-12-27
- **Target enrollment:** 294 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181738, "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02181738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*